Breaking News

GSK Acquires IDRx

IDRx’s lead molecule IDRX-42 complements GSK’s growing pipeline of targeted therapeutics for cancers originating in the gastrointestinal tract.

Author Image

By: Charlie Sternberg

Associate Editor

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). The acquisition includes IDRX-42, an investigational, highly selective tyrosine kinase inhibitor (TKI) specifically designed to enhance outcomes for patients with gastrointestinal stromal tumors (GIST). IDRX-42 exhibits activity against all clinically relevan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters